Sinopharm Group Co L (SHTDF) 4.8000 $SHTDF Prov
Post# of 273318
Posted On: 09/25/2016 9:18:47 PM
Sinopharm Group Co L (SHTDF) 4.8000 $SHTDF
Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm a-Think Pharmaceutical Co., Ltd
BusinessWire - Mon May 18, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"
, today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015.
PVCT: 0.11 (+0.01)
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
BusinessWire - Fri Nov 14, 5:00AM CST
Provectus Biopharmaceuticals, Inc. (NYSE MKT VCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.
PVCT: 0.11 (+0.01)
Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
PR Newswire - Wed Oct 22, 6:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT: 0.11 (+0.01)
Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm a-Think Pharmaceutical Co., Ltd
BusinessWire - Mon May 18, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company" , today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015. PVCT: 0.11 (+0.01)
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
BusinessWire - Fri Nov 14, 5:00AM CST
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term. PVCT: 0.11 (+0.01)
Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
PR Newswire - Wed Oct 22, 6:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT: 0.11 (+0.01)
(0)
(0)